Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

TATA Health International Holdings Limited
TATA 健康國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1255)

INSIDE INFORMATION
PROFIT WARNING

This announcement is made by TATA Health International Holdings Limited (the "**Company**", together with its subsidiaries, collectively referred to as the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors ("**Director(s)**") of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary assessment of the Group's unaudited consolidated financial statements for the six months ended 30 June 2026 (the "**Reporting Period**") and other information currently available to the Board, it is expected that the Group would record a loss attributable to owners of the Company of approximately HKD$12,399,000 for the Reporting Period, as compared to a profit attributable to owners of the Company of approximately HK$20,596,000 for the corresponding period in 2025.

The Board considers that the turning from a profit, to a loss, attributable to owners of the Company for the Reporting Period is primarily attributable to a one-off gain on disposal of subsidiaries in the amount of approximately HK$34.7 million during the corresponding period in 2025. However, there is no such gain on disposal of subsidiaries during the Reporting Period, which results in a loss for the Reporting Period.

This profit warning announcement is only based on the preliminary review on the unaudited consolidated financial information of the Group, which have neither been reviewed nor audited by the Company's auditors, nor reviewed by the Company's audit committee and may be subject to finalisation and possible adjustments arising from further review.

As at the date of this announcement, the Company is in the process of finalising the interim results of the Group for the Reporting Period. The financial results of the Group for the Reporting Period will only be ascertained when all the relevant results are finalised. The interim results announcement of the Group for the Reporting Period is expected to be announced in due course.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
TATA Health International Holdings Limited
Zhang Ming Qi
Executive Director

Hong Kong, 27 August 2026

As at the date of this announcement, the Board comprises an executive Director, namely, Mr. Zhang Ming Qi; a non-executive Director, namely, Mr. Chen Qi; and four independent non-executive Directors, namely, Ms. Huang Lin, Mr. Li Liang, Mr. Du Jianfeng and Mr. Tan Kaiguo.